Targeting pancreatic cancer with gemcitabine

Gemcitabine is an effective anticancer drug in pancreatic cancer, but it's hard to get enough of the drug into the tumor without harming the healthy tissues around. In a study published in Nucleic Acid Therapeutics, U.S. researchers have tagged gemcitabine polymers with an RNA aptamer, a short strand of RNA, designed to bind to epidermal growth factor receptor (EGFR). This is overexpressed on the surface of many pancreatic cancer cells. If this approach works, it could be adapted for other drugs and other targets. Abstract | More

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…